Silexion Therapeutics Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Silexion Therapeutics Corp (NASDAQ:SLXN) is a clinical-stage biotechnology company that discovers, develops and commercializes RNA interference (RNAi)-based therapies and proprietary delivery systems for the treatment of KRAS-driven solid tumors, including pancreatic, colorectal, lung, gastric and glioblastoma cancers. The company offers SIL-204, a second-generation siRNA microparticle platform utilizing PLG technology for intratumoral and systemic (subcutaneous) administration that targets mutant KRAS oncogenes such as G12D, G12V, G12R, G12C, G13D, G12A, G13C and Q61H to inhibit tumor growth and metastasis; first-generation products including SiG12D-LODER (completed Phase 2 trials showing improved survival trends in locally advanced pancreatic cancer), Prostate-LODER (preclinical for prostate cancer) and GBM-LODER (preclinical for glioblastoma); and advanced RNAi formulations enhanced through targeted drug delivery via the LODER (LOcal Drug EluteR) system. Founded in 2008 and headquartered in Jerusalem, Israel, with operations centered in Modi'in-Maccabim-Re'ut and Tel Aviv regions, Silexion focuses on oncology segments targeting KRAS-mutated cancers in patients unresponsive to standard chemotherapy, primarily in Israel, the European Union and the United States. Recent developments include the August 2024 completion of a business combination with Moringa Acquisition Corp to list on Nasdaq; a September 2025 partnership with AMS Advanced Medical Services GmbH as contract research organization for Phase 2/3 trials of SIL-204; an April 2025 collaboration with Catalent for siRNA formulation and clinical manufacturing; positive feedback from German health authorities in December 2025 on Phase 2/3 trial design; completion of toxicology studies and preclinical data in 2025 demonstrating up to 99.7% KRAS inhibition across multiple human cell lines and efficacy against metastases; $6.0 million public offering and over $9 million in additional funding in September 2025; a 1-for-15 reverse share split in July 2025; Nasdaq compliance regained in September 2025; and plans for Phase 2/3 trial initiation in the first half of 2026 with regulatory submissions in Israel and the EU.
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics to Attend BIO International Convention 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics (NASDAQ:SLXN) Shares Down 0.9% – Should You Sell?
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data